Kite Pharma (KITE) Tops Q4 EPS by 44c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Kite Reports Fourth Quarter and Full Year 2016 Financial Results
February 28, 2017 8:00 AM ESTStrong Execution Across Clinical Development, Pipeline, Manufacturing and Pre-Commercial Activities in 2016 On Track to Complete Rolling Biologics License Application to the U.S. Food and Drug Administration for Axicabtagene Ciloleucel by End of First Quarter 2017 Potential U.S. Approval and Launch of Axicabtagene Ciloleucel Expected in 2017 Conference Call to Be Held Today at 9:00 AM Eastern Time
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today provided a corporate update and reported fourth quarter and full-year 2016... More
